BPC-157 + TB-500 Blend Dosage Calculator (Wolverine Stack)
Two research peptides premixed in one vial. Because they share a solution you cannot dose one without dosing the other, and the one study that tested the pair found no benefit from combining them.
Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.
Not approved; neither component is on any FDA list
Both components were on the FDA's 503A Category 2 list from September 2023 and both were removed on 22 April 2026 when the nominations were withdrawn — neither moved to Category 1, so both remain outside the statutory conditions for compounding. They appear on the FDA's Category 2 page only under “nominated but withdrawn”. The July 2026 advisory committee votes recommending each of them are non-binding. There is no FDA recognition of the blend as a product, and no identity standard for the mixture.
No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.
Anti-doping: Prohibited at all times. Contains BPC-157 (class S0) and thymosin beta-4 (class S2).
Key facts
- Half-life
- Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
- Also sold as
- BPC157 TB500, healing stack, Wolverine stack, Wolverine peptide stack
Doses used in published studies
These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.
How good is the evidence?
One published study has tested the two peptides together, in rats, and its result was negative: combining them conferred no additional benefit over either peptide alone. Beyond that there is nothing — no pharmacokinetics, no human trial, and no compatibility or stability study of the two peptides co-formulated in one vial. The nearest thing to human data is a retrospective review of 17 knee-injection patients, four of whom received both peptides; it had no control group and recorded no doses, and the combination subgroup did slightly worse than BPC-157 alone. Separately, neither peptide has human evidence for injury repair.
What is the Wolverine stack?
“Wolverine stack” is a marketing name, not a drug. It means BPC-157 and TB-500 (a synthetic fragment sold as thymosin beta-4) taken together — either as two separate vials or premixed in one, most often 5 mg + 5 mg or 10 mg + 10 mg. The name promises fast healing; no regulator, manufacturer or clinical trial defines it, so two products sold under it can hold different amounts and ratios.
Neither component is FDA-approved, neither is on any FDA compounding list, and both are prohibited in sport at all times under the WADA list. The only study that tested the pair together was in rats, and it found no added benefit over either peptide alone.
BPC-157 + TB-500 blend calculator: what one draw contains
This page is the calculator for both the BPC-157 + TB-500 blend and the product nickname “Wolverine stack.” They are the same search intent: a fixed-ratio vial containing the two peptides. Creating a second Wolverine calculator would duplicate this page, split its relevance and invite the two URLs to compete for the same query.
Enter the amount of each peptide printed on the vial rather than the total on the front label. In a 10 mg + 10 mg blend reconstituted with 3 mL, each component is 3.33 mg/mL. A 0.15 mL draw — 15 units on a U-100 syringe — therefore contains 500 mcg of BPC-157 and 500 mcg of TB-500. That is concentration arithmetic, not a dosing recommendation.
Why a Wolverine stack dosage chart cannot be evidence-based
No human trial has established a dose or schedule for the combination. The only published experiment that administered both together used rats, used a 1:6 BPC-157-to-TB-500 ratio rather than the 1:1 commercial ratio, and found no additional benefit from combining them.
A chart can show how the vial's stated contents translate into concentration, millilitres and syringe units. It cannot turn a vendor-selected ratio into a clinically established protocol. Keeping those two jobs separate is the difference between a reconstitution calculator and medical advice.
Common questions
Sources
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- RegulatorFDA· 2026-05-14Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- RegulatorFDACertain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- RegulatorFDA· 2026-07July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- RegulatorWorld Anti-Doping Agency· 2026WADA 2026 Prohibited List
- Published studyJoint Diseases and Related Surgery 2026;37(3):822–37· 2026-07Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study
- Published studyAlternative Therapies in Health and Medicine 2021;27(4):8–13· 2021-07Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
- Published studyAmerican Journal of Sports Medicine 2026;54(1):223–9· 2026-01Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- RegulatorFDA / CDER· 2005-07Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers — Guidance for Industry (Table 1, body surface area conversion factors)
- RegulatorFDACompounding Risk Alerts